Gradientech announces appointment of Hilja Ibert and Nedal Safwat to Board of directors
The diagnostics company Gradientech today announces the appointment of Dr Hilja Ibert and Dr Nedal Safwat to the Gradientech Board of Directors, effective May 9, 2023. Following the new appointments, the Board will comprise six directors.
Dr Hilja Ibert brings more than 30 years of experience from the clinical diagnostics industry at international companies like Hologic, Becton Dickinson and bioMérieux, including Vice President and General Manager positions within the business areas of Diagnostic systems and Bioscience. Dr Hilja Ibert is currently CEO of Gentian Diagnostics, a Norwegian publicly listed company having products on the international immunodiagnostics market.
“I feel honored having been selected to become part of the Gradientech Board. The innovative products from Gradientech are addressing preeminent needs in the clinical diagnostics market and I am looking forward to support the talented team at Gradientech during this exciting phase of the company,” says Dr Hilja Ibert.
Dr Nedal Safwat is currently the Vice President and Head of Molecular Diagnostics North America at Qiagen, a global leading company in molecular diagnostics. Previously to his current engagement, Dr Nedal Safwat brings more than 15 years of experience from the clinical diagnostics industry, specifically with business unit and commercial roles at bioMérieux covering microbiology applications including bacteria identification, antibiotic susceptibility testing, antibiotic resistance, and sepsis detection products.
Ted Elvhage and Simon Turner did not stand for re-election at the Gradientech Annual General Meeting. Ted Elvhage has been Board director since 2014, and Simon Turner since 2020.
“We are pleased to welcome Hilja Ibert and Nedal Safwat to the Gradientech Board,” says Gisela Sitbon, Chairman of the Board. “Their extensive commercial experience within the global clinical microbiology field, combined with deep technology knowledge within the antibiotic susceptibility testing product-line, will be invaluable to Gradientech as we now grow our business and head towards clinical studies in the US. I would also like to thank Ted Elvhage and Simon Turner for their dedicated work during many years in the Gradientech Board.”
For further information, please contact:
Sara Thorslund, PhD, CEO Gradientech
Tel: +46 736 29 35 80
About Gradientech
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC® allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.
